We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.
- Authors
Montes, Vera; Sousa, Sandra; Pita, Fernando; Guerreiro, Rui; Carmona, Cátia
- Abstract
In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma. It acts as an immune checkpoint inhibitor, binding and blocking cytotoxic T-lymphocyte antigen-4 in order to increase the antitumor immune response. There are several reports of autoimmune responses after its use. A 74-year-old man developed a mild rash and pruritus a few hours after the second infusion of ipilimumab and 24 h after the third dose of ipilimumab, he presented with shortness of breath, proximal limb muscle weakness, and diplopia. Repetitive nerve stimulation was consistent with a postsynaptic neuromuscular junction disorder. He began therapy with corticosteroids and pyridostigmine and ipilimumab was discontinued. Following ipilimumab suspension, the patient started to improve gradually. Here, we describe a rare case of myasthenia gravis presumably related with ipilimumab's therapy. A better knowledge of these agents is necessary, in order to identify characteristics or biomarkers that may be associated with the development of potentially serious autoimmune responses.
- Subjects
IPILIMUMAB; MELANOMA
- Publication
Frontiers in Neurology, 2018, p1
- ISSN
1664-2295
- Publication type
Article
- DOI
10.3389/fneur.2018.00150